Cargando…
Biomarker Panel for the Diagnosis of Pancreatic Ductal Adenocarcinoma
A single tumor marker has a low diagnostic value in pancreatic cancer. Combinations of multiple biomarkers and unique analysis algorithms can be applied to overcome these limitations. This study sought to develop diagnostic algorithms using multiple biomarker panels and to validate their performance...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7352313/ https://www.ncbi.nlm.nih.gov/pubmed/32492943 http://dx.doi.org/10.3390/cancers12061443 |
_version_ | 1783557608640086016 |
---|---|
author | Kim, Hongbeom Kang, Kyung Nam Shin, Yong Sung Byun, Yoonhyeong Han, Youngmin Kwon, Wooil Kim, Chul Woo Jang, Jin-Young |
author_facet | Kim, Hongbeom Kang, Kyung Nam Shin, Yong Sung Byun, Yoonhyeong Han, Youngmin Kwon, Wooil Kim, Chul Woo Jang, Jin-Young |
author_sort | Kim, Hongbeom |
collection | PubMed |
description | A single tumor marker has a low diagnostic value in pancreatic cancer. Combinations of multiple biomarkers and unique analysis algorithms can be applied to overcome these limitations. This study sought to develop diagnostic algorithms using multiple biomarker panels and to validate their performance in the diagnosis of pancreatic ductal adenocarcinoma (PDAC). We used blood samples from 180 PDAC patients and 573 healthy controls. Candidate markers consisted of 11 markers that are commonly expressed in various cancers and which have previously demonstrated increased expression in pancreatic cancer. Samples were divided into training and validation sets. Five linear or non-linear classification methods were used to determine the optimal model. Differences were identified in 10 out of the 11 markers tested. We identified 2047 combinations, all of which were applied to 5 separate algorithms. The new biomarker combination consisted of 6 markers (ApoA1, CA125, CA19-9, CEA, ApoA2, and TTR). The area under the curve, specificity, and sensitivity were 0.992, 95%, and 96%, respectively, in the training set. Meanwhile, the measures were 0.993, 96%, and 93% in the validation set. This study demonstrated the utility of multiple biomarker combinations in the early detection of PDAC. A diagnostic panel of 6 biomarkers was developed and validated. These algorithms will assist in the early diagnosis of PDAC. |
format | Online Article Text |
id | pubmed-7352313 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-73523132020-07-21 Biomarker Panel for the Diagnosis of Pancreatic Ductal Adenocarcinoma Kim, Hongbeom Kang, Kyung Nam Shin, Yong Sung Byun, Yoonhyeong Han, Youngmin Kwon, Wooil Kim, Chul Woo Jang, Jin-Young Cancers (Basel) Article A single tumor marker has a low diagnostic value in pancreatic cancer. Combinations of multiple biomarkers and unique analysis algorithms can be applied to overcome these limitations. This study sought to develop diagnostic algorithms using multiple biomarker panels and to validate their performance in the diagnosis of pancreatic ductal adenocarcinoma (PDAC). We used blood samples from 180 PDAC patients and 573 healthy controls. Candidate markers consisted of 11 markers that are commonly expressed in various cancers and which have previously demonstrated increased expression in pancreatic cancer. Samples were divided into training and validation sets. Five linear or non-linear classification methods were used to determine the optimal model. Differences were identified in 10 out of the 11 markers tested. We identified 2047 combinations, all of which were applied to 5 separate algorithms. The new biomarker combination consisted of 6 markers (ApoA1, CA125, CA19-9, CEA, ApoA2, and TTR). The area under the curve, specificity, and sensitivity were 0.992, 95%, and 96%, respectively, in the training set. Meanwhile, the measures were 0.993, 96%, and 93% in the validation set. This study demonstrated the utility of multiple biomarker combinations in the early detection of PDAC. A diagnostic panel of 6 biomarkers was developed and validated. These algorithms will assist in the early diagnosis of PDAC. MDPI 2020-06-01 /pmc/articles/PMC7352313/ /pubmed/32492943 http://dx.doi.org/10.3390/cancers12061443 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Kim, Hongbeom Kang, Kyung Nam Shin, Yong Sung Byun, Yoonhyeong Han, Youngmin Kwon, Wooil Kim, Chul Woo Jang, Jin-Young Biomarker Panel for the Diagnosis of Pancreatic Ductal Adenocarcinoma |
title | Biomarker Panel for the Diagnosis of Pancreatic Ductal Adenocarcinoma |
title_full | Biomarker Panel for the Diagnosis of Pancreatic Ductal Adenocarcinoma |
title_fullStr | Biomarker Panel for the Diagnosis of Pancreatic Ductal Adenocarcinoma |
title_full_unstemmed | Biomarker Panel for the Diagnosis of Pancreatic Ductal Adenocarcinoma |
title_short | Biomarker Panel for the Diagnosis of Pancreatic Ductal Adenocarcinoma |
title_sort | biomarker panel for the diagnosis of pancreatic ductal adenocarcinoma |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7352313/ https://www.ncbi.nlm.nih.gov/pubmed/32492943 http://dx.doi.org/10.3390/cancers12061443 |
work_keys_str_mv | AT kimhongbeom biomarkerpanelforthediagnosisofpancreaticductaladenocarcinoma AT kangkyungnam biomarkerpanelforthediagnosisofpancreaticductaladenocarcinoma AT shinyongsung biomarkerpanelforthediagnosisofpancreaticductaladenocarcinoma AT byunyoonhyeong biomarkerpanelforthediagnosisofpancreaticductaladenocarcinoma AT hanyoungmin biomarkerpanelforthediagnosisofpancreaticductaladenocarcinoma AT kwonwooil biomarkerpanelforthediagnosisofpancreaticductaladenocarcinoma AT kimchulwoo biomarkerpanelforthediagnosisofpancreaticductaladenocarcinoma AT jangjinyoung biomarkerpanelforthediagnosisofpancreaticductaladenocarcinoma |